Perjeta®, pertuzumab, is approved for use in combination with Herceptin® (trastuzumab) and docetaxel in people who have HER2 positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti HER2 therapy or chemotherapy for metastatic breast cancer.
Perjeta® is approved for use in combination with Herceptin® (trastuzumab) and chemotherapy for:
- use prior to surgery (neoadjuvant treatment) in people with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive). PERJETA should be used as part of a complete treatment regimen for early breast cancer.
- use after surgery (adjuvant treatment) in people with HER2-positive early breast cancer that has a high likelihood of coming back.
